CytoMed, Inc. 1352 Middlebury Drive, Westfield, IN 46074 Tel. 941-751-2872 Fax. 317-816-1243 W E L L N E S S on purpose
August
24, 2011
Subject:
CoQLIFE
To Our Dear Customers:
Over the past couple of months we
have received some inquiries asking if our CoQLIFE is the oxidized ubiquinone
or the reduced ubiquinol; the difference being two hydrogen ions. Our CoQLIFE is ubiquinone. And here are the reasons Dr. Judy prefers to
use ubiquinone rather than ubiquinol:
1. Ubiquinone has been researched
for more than 40 years. There are
literally 10’s of thousands of studies using ubiquinone. Commercially available ubiquinol is
relatively new and has been researched for less than 5 years. There remain several unresolved questions as
to its stability, absorption, and safety.
2. The CoQ10 synthesized in the
human body is ubiquinone. It is true
that the greater percent of CoQ10 is converted from ubiquinone to ubiquinol to
be used by the body cells as a potent antioxidant. (Ubiquinone is used for energy
production.) However, in this conversion
some essential biochemical changes occur.
Ubiquinone is first converted to a semiquinone and then to
ubiquinol. When ubiquinol is ingested
rather than ubiquinone this important step is bypassed and we really don’t yet
know what the ramification of skipping this step may be.
3. Ubiquinol costs three times more
than ubiquinone. There are a very small
percentage of people worldwide who have a genetic aberration that causes them
to be unable to absorb ubiquinone and, for them, ubiquinol appears to be a
viable alternative. But the majority of
people can absorb CoQ10, when it is properly prepared (single molecules in a
lipid carrier). In addition, there is no
proof that ubiquinol is absorbed as ubiquinol.
In the presence of oxygen, ubiquinol is converted to ubiquinone. There is oxygen in the stomach so when the
ubiquinone enters the digestive tract it may very well be converted to
ubiquinone. So why pay more for unstable
ubiquinol?
4. Some of you may have heard that
the 15 year study using CoQ10 in elderly, more severe Parkinson’s patients had
a negative result. In other words they
did not prove that CoQ10 ameliorated the debilitating symptoms of Parkinson’s
disease. However, it was found that
when used in younger, less severe cases of Parkinson’s, CoQ10 did have a
benefit in that it reduced or eliminated the symptoms. The reason for the failure of the study in
elderly patients may be due to the poor quality CoQ10 product used. They used dry powder, crystal CoQ10 and were
not able to raise the blood levels to a therapeutic level. To be therapeutic CoQ10 blood levels need to
be above 3.5 ug/ml; in this study, using 1600 to 2400 mg of CoQ10, they were
not able to raise the blood levels above 3.0 ug/ml. We are currently using 250 mg of CoQLIFE in
these types of patients and are able to raise the blood levels above 4.4
ug/ml. We have been advising the NIH
sponsors for 10 years that they are using the wrong CoQ10 formulation and
therefore are not able to raise the blood levels to an adequate level for
treatment of advanced Parkinson’s.
Sincerely,
____________________
William V. Judy, PhD
President
CytoMed, Inc.
941.751.2872